Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity.

Transplantation and cellular therapy·2026
Same author

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Transplantation and cellular therapy·2026
Same author

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Transplantation and cellular therapy·2026
Same author

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Transplantation and cellular therapy·2026
Same author

Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemia.

Haematologica·2026
Same author

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026

Related Experiment Video

Updated: Feb 23, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

746

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.

Patrick A Brown, Bijal Shah, Amir Fathi

    Journal of the National Comprehensive Cancer Network : JNCCN
    |September 7, 2017
    PubMed
    Summary

    Managing relapsed or refractory acute lymphoblastic leukemia (ALL) is challenging. These NCCN Guidelines Insights offer updated treatment recommendations for R/R ALL based on current evidence.

    More Related Videos

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
    06:08

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

    Published on: February 10, 2023

    1.9K
    Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
    09:57

    Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

    Published on: March 5, 2018

    30.7K

    Related Experiment Videos

    Last Updated: Feb 23, 2026

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    746
    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
    06:08

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

    Published on: February 10, 2023

    1.9K
    Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
    09:57

    Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

    Published on: March 5, 2018

    30.7K

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Guidelines

    Background:

    • Prognosis for newly diagnosed acute lymphoblastic leukemia (ALL) has improved due to advancements in chemotherapy, targeted agents, and transplantation.
    • Management of relapsed or refractory (R/R) ALL remains a significant clinical challenge with a poor prognosis.

    Framework:

    • The National Comprehensive Cancer Network (NCCN) Guidelines for ALL provide evidence-based treatment recommendations.
    • This document summarizes key updates and discussions from the NCCN panel regarding R/R ALL management.

    Implementation:

    • Focuses on summarizing recent NCCN recommendations for R/R ALL.
    • Highlights critical updates and supporting data for treatment strategies.

    Implications:

    • Aims to guide clinicians in managing challenging R/R ALL cases.
    • Provides a concise overview of current best practices for R/R ALL treatment based on expert consensus.